

1 **Title: The clinical course of COVID-19 in the outpatient setting: a prospective cohort study**

2 **Running title:** The course of outpatient COVID-19.

3 **Authors:** Paul W. Blair<sup>1,2\*</sup> Diane Brown<sup>1</sup>, Minyoung Jang<sup>1</sup>, Annukka A.R. Antar<sup>1</sup>, Jeanne C. Keruly<sup>1</sup>,

4 Vismaya S. Bachu<sup>1</sup>, Jennifer L. Townsend<sup>1</sup>, Jeffrey Tornheim<sup>1</sup>, Sara C. Keller<sup>1</sup>, Lauren Sauer<sup>3</sup>, David L.

5 Thomas<sup>1</sup>, Yukari C. Manabe<sup>\*1</sup> on behalf of the Ambulatory COVID Study Team\*\*

6 **\*Corresponding Author:** Yukari C. Manabe, MD. Division of Infectious Diseases, Department of

7 Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA; email:

8 [ymanabe@jhmi.edu](mailto:ymanabe@jhmi.edu) \*\***Ambulatory COVID Study Team:** Andrea Cox, Chris Heaney, Sabra Klein, Shruti

9 Mehta, Heba Mostafa, Andy Pekosz, Nora Pisanic, Derek Armstrong, Razvan Azamfirei, Brittany Barnaba,

10 Curtisha Charles, Taylor Church, Samantha N. Walch, Weiwei Dai, Christine B. Payton, Joelle Fuchs, Justin

11 Hardick, Jeffrey Holden, Jaylynn R. Johnstone, Kate Kruczynski, Oyinkansola Kusemiju, Anastasia

12 Lambrou, Lucy Li, Kirsten Littlefield, Manuela Plazas Montana, Caroline Popper, Michelle Prizzi, Carolyn J

13 Reuland, Thelio Sewell, Amanda Tuchler.

14 **Affiliation:** <sup>1</sup>Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of

15 Medicine, Baltimore, MD, USA; <sup>2</sup>Austere environments Consortium for Enhanced Sepsis Outcomes,

16 Henry M. Jackson Foundation, Bethesda, MD, USA; <sup>3</sup>Department of Emergency Medicine, Johns Hopkins

17 University School of Medicine, Baltimore, MD, USA.

18 **Key words:** Coronavirus Infections / epidemiology; Middle Aged; Recovery of Function; Ambulatory

19 Care; Treatment Outcome

20

21

22 **ABSTRACT**

23 **Background:** Outpatient COVID-19 has been insufficiently characterized.

24 **Objective:** To determine the progression of disease and subsequent determinants of hospitalization.

25 **Design:** A prospective outpatient cohort.

26 **Setting:** Outpatients were recruited by phone between April 21 to June 23, 2020 after receiving  
27 outpatient or emergency department testing within a large health network in Maryland, USA.

28 **Participants:** Outpatient adults with positive RT-PCR results for SARS-CoV-2.

29 **Measurements:** Symptoms, portable pulse oximeter oxygen saturation (SaO<sub>2</sub>), heart rate, and  
30 temperature were collected by participants on days 0, 3, 7, 14, 21, and 28 after enrollment. Baseline  
31 demographics, comorbid conditions were evaluated for risk of subsequent hospitalization using negative  
32 binomial, logistic, and random effects logistic regression.

33 **Results:** Among 118 SARS-CoV-2 infected outpatients, the median age was 56.0 years (IQR, 50.0 to 63.0)  
34 and 50 (42.4%) were male. Among those reporting active symptoms, the most common symptoms  
35 during the first week since symptom onset included weakness/fatigue (67.3%), cough (58.0%), headache  
36 (43.8%), and sore throat (34.8%). Participants returned to their usual health a median of 20 days (IQR,  
37 13 to 38) from the symptom onset, and only 65.5% of respondents were at their usual health during the  
38 fourth week of illness. Over 28 days, 10.9% presented to the emergency department and 7.6% required  
39 hospitalization. Individuals at the same duration of illness had a 6.1 times increased adjusted odds of  
40 subsequent hospitalization per every percent decrease in home SaO<sub>2</sub> (95% confidence interval [CI]: 1.41  
41 to 31.23, p=0.02).

42 **Limitations:** Severity and duration of illness may differ in a younger population.

43 **Conclusion:** Symptoms often persisted but uncommonly progressed to hospitalization. Home SaO<sub>2</sub>  
44 might be an important adjunctive tool to identify progression of COVID-19.

45 **Registration:** Clinicaltrials.gov NCT number: NCT04496466

46 **Funding Source:** The Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases Discovery Program  
47 and the Johns Hopkins University School of Medicine

48 **Abstract word count: 270**

49

## 50 **INTRODUCTION**

51 SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the cause of the COVID-19 pandemic  
52 that has affected nearly every region of the world and by August 8<sup>th</sup>, 2020 is responsible for the deaths  
53 of more than 723,000 people(1). In persons who are hospitalized, the clinical features of COVID-19 and  
54 disease course are well described(2-4). However, most SARS-CoV-2 infected persons are not  
55 hospitalized, and relatively little is known about the progression of symptoms, clinical outcomes, and  
56 severity predictors among outpatients(5-7). The prevalence and time course of unique clinical features  
57 of COVID-19 such as the occurrence of low oxygen saturations with a delayed patient sense of dyspnea,  
58 or 'silent hypoxemia,' has yet to be fully characterized(8-10). Additionally, seroprevalence studies  
59 suggest that the number of outpatient cases are much greater than have been reported(11).

60 To investigate COVID-19 in the home setting, a prospective outpatient observational cohort was  
61 recruited and studied using structured measurements to characterize the course of disease. To better  
62 study risk factors for severe disease, the cohort recruitment efforts enriched for older individuals (12).  
63 Given the dominance of pulmonary syndromes in those hospitalized and to investigate the incidence of  
64 asymptomatic hypoxemia, we supplemented home monitoring with daily pulse oximetry(9).

65

## 66 **METHODS**

### 67 **Study design**

68 In an Institutional Review Board-approved study, persons  $\geq$  age 18 who attended one of the Johns  
69 Hopkins Health System COVID-19 testing sites and tested positive for SARS-CoV-2 were offered  
70 enrollment in the study, excluding patients hospitalized at the time of screening. To maximize  
71 recruitment of older persons, we focused recruitment to individuals who were midlife adults or older  
72 ( $\geq$ 40 years) (12). Verbal consent was obtained via telephone. After providing verbal consent a study

73 coordinator contacted the participant to confirm their willingness to participate and verify the shipping  
74 address to which a study self-testing kit was shipped and received by the participant within 24-48 hours.  
75 This kit contained a thermometer (CVS Health, Woonsocket, RI), a pulse oximeter (Zewa, Fort Myers, FL)  
76 and supplies for self-testing.(13) A study coordinator scheduled a video or phone study visit (Day 0) to  
77 occur upon receipt of the study kit to instruct participants on self-testing procedures and appropriate  
78 use of the pulse oximeter. Study visits occurred via phone for days 0, 3, 7, 14, and 21. Participants  
79 attended an in-person follow-up visit between study days 28 and 60 if they were asymptomatic at the  
80 time, consistent with local hospital infection control procedures.

81  
82 Vital signs (heart rate, oxygen saturation, and temperature) were prospectively collected and recorded  
83 by participants for 14 days and reviewed with the study coordinator at each study visit. Participants  
84 were requested to call the study team and their primary care physician for oxygen saturation values  
85 <93%. At each time point participants completed a 32-item influenza Patient –Reported Outcome (FLU-  
86 PRO) (14) questionnaire verbally over the phone with the study coordinator. This questionnaire assessed  
87 participants’ sense of physical well-being including symptoms. Symptoms were reported using a Likert  
88 scale. This instrument has been previously validated for patient reported outcomes for influenza and  
89 other respiratory viruses(14-17). The FLU-PRO was modified to allow participants to report symptoms  
90 they perceived to be related to COVID-19 that were not already listed on the questionnaire (e.g. ageusia  
91 and anosmia). These additional items were not included in the mean FLU-PRO score. Study data were  
92 collected and managed using a REDCap electronic data capture tool hosted at Johns Hopkins University  
93 (18).

94  
95 Preceding symptoms were recorded at enrollment and present symptoms recorded on study days.  
96 Summary statistics including prevalence, incidence, and duration were calculated for baseline

97 demographics, baseline comorbidities and for time-varying parameters such as vital signs and modified  
98 FLU-PRO symptoms. FLU-PRO total score means and symptom domain (e.g. respiratory) means were  
99 calculated (16). To identify common symptom patterns at the onset of illness, we evaluated the  
100 frequency of combinations of CDC COVID-19 case definition symptoms in addition to diarrhea and  
101 weakness using an upset plot (19). Symptom prevalence was categorized by week of illness. To reduce  
102 the effect of recall bias, prior symptoms were included in the determination of prevalence by week of  
103 illness only if symptoms had started within a week of enrollment. To evaluate the correlation between  
104 oxygen saturation at rest and with ambulation, a Pearson's correlation was performed, and a Bland-  
105 Altman plot was created. Kaplan-Meier plots were created to describe the time from symptom onset to  
106 a return to usual health and the time to a return to usual activities. After checking the proportional  
107 hazards assumption, Cox regression was performed to evaluate for baseline demographics and duration  
108 of illness affecting activities. Univariate negative log binomial regression was performed to evaluate the  
109 association between age, sex, baseline comorbid conditions (dichotomous), heart rate (continuous),  
110 temperature (continuous), oxygen saturation (continuous) on the occurrence of a subsequent  
111 hospitalization. Logistic regression was performed for significant values and an Area Under the Curve  
112 (AUROC) determined. A random effects logistic regression model was used to evaluate for an  
113 association oxygen level as a time varying covariate and subsequent hospitalization. Days since symptom  
114 onset (continuous), age (continuous) and resting oxygen saturation (continuous), and an interaction  
115 term between duration of illness and resting oxygen saturation (continuous) were candidate model  
116 covariates. Models were compared using Akaike information criterion (AIC) model estimates. Persons  
117 that withdrew or were lost to follow-up were excluded from regression analyses. The sample size  
118 includes that which was operationally obtainable during the described study period in a Master Protocol  
119 study (clinicaltrials.gov NCT04496466). Analyses were performed using Stata version 16.0 (StataCorp

120 LLC, College Station, TX, USA) and figures were created using Stata or R statistical platform version 4.0.1  
121 (R Foundation).

122

## 123 **RESULTS**

124 From April 21 to June 23, 2020, 118 participants enrolled a median of 5.0 (3.0-10.0) days from symptoms  
125 onset, while a total of 115 others were contacted but refused participation (Figure 1). Participants were  
126 a median of 56.0 (IQR, 50.0 to 63.0) years of age, 42.4% male (N = 50), and the median Charlson  
127 Comorbidity Index was 2 (IQR, 1 to 3) (Table 1). In the prior two weeks before developing symptoms,  
128 40.2% (N=39) had contact with someone with confirmed COVID-19 and an additional 21.9% (N=21) had  
129 contact with someone with symptoms concerning for unconfirmed COVID-19. The duration of symptoms  
130 at enrollment was 5.0 days (IQR, 3.0 to 10.0) (Table 1).

131

### 132 *Symptoms and physiologic parameters at the onset of illness*

133 The most common initial symptoms were measured or suspected fever (28.0%), dry cough (23.7%), body  
134 aches (21.2 %), weakness or fatigue (20.3 %), and headache (17.0 %)(Appendix Figure S1). There were  
135 five (4.2%) asymptomatic participants and four patients (3.4%) who were pauci-symptomatic (one  
136 symptom prior to or at enrollment). Asymptomatic patients were tested because they had a positive  
137 contact (N=3) or during screening for medical encounters (N=2).

138

### 139 *Symptoms and physiologic parameters during the clinical course of disease*

140 Among those reporting symptoms, the most common during the first week since onset included  
141 weakness/fatigue (67.3%), cough (58.0%), headache (43.8%), and sore throat (34.8%) (Appendix Table 1;  
142 Figure 2A). Repeated unexpected symptoms included a skin burning sensation (N=3) and a smell of  
143 burning wood (N=2). During the first month of illness, the prevalence of symptoms decreased but a

144 substantial proportion of individuals still reported weakness (15.4%) or a dry cough (18.3%) (Figure 2A  
145 and 2B).

146  
147 The effect of symptoms on activities of daily living and illness severity varied greatly at any given point  
148 and over time (Figure 3). Interestingly, during the first week of illness, 43.1% of patients reported no  
149 effect of their symptoms on daily activities. Participants returned to their usual health a median of 20  
150 days (IQR, 13 to 38) from the onset of symptoms, and the median time to returning to usual activities  
151 was 17 days (IQR, 11 to 28) from symptom onset (Figure 3A-B). Baseline factors of age, sex, or comorbid  
152 conditions were not associated with a delay in return to health or to usual activities with unadjusted Cox  
153 proportional hazards regression (data not shown). Notably, while the majority 63.7% of participant had  
154 no symptoms or only had mild symptoms during the first week of illness a substantial proportion  
155 continued to have mild or moderate symptoms for over one month (Figure 3C-E). During the third and  
156 fourth week of illness, only 52.6% and 65.5% of respondents had returned to their usual health,  
157 respectively.

158  
159 *Oxygen saturation, heart rate, temperature, and subsequent hospitalization*

160 The initial median oxygen saturation values (SaO<sub>2</sub>) at rest were 98.0% (IQR, 96.0 to 98.5) and during  
161 ambulation were 97.0% (IQR, 95.0 to 98.0) (Table 1). Correlation between walking and ambulatory SaO<sub>2</sub>  
162 was 0.61, with a larger difference between values noted at lower oxygen saturations (Appendix Figure  
163 S2A). Resting SaO<sub>2</sub> at 92% or less occurred among 11.1% (N=8) of participants at a median 11.5 days  
164 from symptom onset (IQR, 10, 14), but only accounted for 3.4% of all SaO<sub>2</sub> levels. When evaluating the  
165 mean value of respiratory symptom questions at the time of oxygen measurements, five out of eight  
166 individuals with an ambulatory SaO<sub>2</sub> ≤92% and two out of five individuals with a resting SaO<sub>2</sub> ≤92 had  
167 mild or no respiratory symptoms (Appendix Figure S2B-C). Additionally, there were 8 participants with at

168 least one low ( $\leq 92\%$ ) ambulatory SaO<sub>2</sub> and 4 participants with at least one low resting home SaO<sub>2</sub> who  
169 did not seek medical attention, despite prior guidance.

170  
171 Low oxygen saturation ( $< 93\%$ ) was the leading factor for 5 participants being sent to the ED, followed by  
172 dyspnea (N=4), diarrhea (N=2), fever (N=1), chest pain (N=1), and elevated blood pressure (N=1). During  
173 the study period, 13 (11.0%) presented to the emergency department and 9 (7.6%) required  
174 hospitalization (Appendix Table S2). The median time from symptom onset to hospitalization was 11  
175 days (IQR, 9 to 12).

176  
177 Baseline demographics and initial study vital signs were evaluated for associations with subsequent  
178 hospitalization. Each year of age was associated with 9% increased odds of subsequent hospitalization  
179 (OR: 1.1, CI, 1.00 to 1.19,  $p=0.04$ ; IRR: 1.1, CI, 1.00 to 1.17,  $p=0.049$ ). Other baseline demographics or  
180 comorbidities were not associated with an increased risk of subsequent hospitalization (Appendix Figure  
181 S3).

182  
183 Among those who were subsequently hospitalized, the initial median SaO<sub>2</sub> at rest was 95.0 percent (IQR,  
184 90.0 to 97.0) and during ambulation was 95.0 percent (IQR, 88.0 to 96.0) (Table 1; Figure 4A-B).

185 Temperature, heart rate, and SaO<sub>2</sub> were plotted over time and stratified by a need for subsequent  
186 hospitalization (Figure 4C-F). However, each percent decrease in value of the first recorded resting SaO<sub>2</sub>  
187 (N=91) was associated with a 30.0% increased relative risk of a subsequent hospitalization (IRR: 1.3, CI:  
188 1.413 to 1.49,  $p=0.004$ ; OR 1.7, CI: 1.18 to 2.37,  $p=0.004$ ). While the initial ambulatory SaO<sub>2</sub> was  
189 similarly associated with subsequent hospitalization (OR: 1.76; CI, 1.24 to 2.48,  $p=0.001$ ), temperature  
190 (OR: 1.5 per degree Fahrenheit; CI, 0.81 to 2.69,  $p=0.20$ ) and heart rate (OR: 1.0 per 10 beats per



191 minute; CI, 0.58 to 1.88,  $p=0.90$ ) were not. The AUROC for the initial SaO<sub>2</sub> for predicting subsequent  
192 hospitalization was 0.85 (CI, 0.71 to 0.89).

193  
194 To further explore the utility of a resting SaO<sub>2</sub>, the performance characteristics of the individual-level  
195 nadir of resting SaO<sub>2</sub> were determined for those within the first week of illness (N=42). The AUROC was  
196 found to be 0.84 (CI, 0.67 to 1.0) for predicting subsequent hospitalization. SaO<sub>2</sub> values of 93% or below  
197 in the first week of illness were specific (92.1%) but not sensitive (50%) for predicting subsequent  
198 hospitalization with a 6.3 positive likelihood ratio. There was a negative likelihood ratio of zero for  
199 subsequent hospitalization among those with a resting oxygen saturation that went no lower than 96%  
200 (Appendix Table S3).

201  
202 To evaluate for the association of oxygen saturation levels over time, a random effects logistic  
203 regression model was fit adjusting for age. The model was more parsimonious according to a lower AIC  
204 when including age as a covariate. Individuals at the same duration of illness were found to have a 6.6-  
205 fold increased crude odds (CI: 1.41 to 31.23,  $p = 0.02$ ) and a 6.1-fold increased adjusted odds of  
206 subsequent hospitalization per every SaO<sub>2</sub> percent decrease (CI: 1.41 to 31.23,  $p=0.02$ ).

207

208

## 209 DISCUSSION

210 This may be the first study to prospectively characterize the incidence, intensity, and duration of  
211 COVID-19 in an outpatient setting. Presenting symptoms were diverse, persistent, and uncommonly  
212 required hospitalization, especially when high ambulatory blood oxygen concentration were sustained.

213 These findings support early observations from hospitalized patients that symptoms may persist  
214 long-term after acute COVID-19 illness (6, 7, 20, 21). Despite outpatient COVID-19 being considered

215 generally mild, we also found that respiratory and systemic symptoms persistent for weeks, notably  
216 longer than with common respiratory viruses(16, 17). Our findings were consistent with a cross-  
217 sectional survey that found that 35% of outpatient COVID-19 positive respondents had not returned to  
218 their usual state of health between 2 to 3 weeks from diagnosis(6). Additionally, cough, fatigue, or  
219 shortness of breath were present among 43%, 35%, and 29%, respectively, among those that initially  
220 reported symptoms(6). In comparison, participants in our cohort reported cough among 23.4%,  
221 weakness or fatigue among 40.8%, and shortness of breath among 11.7% during the third week of  
222 illness regardless of initial symptoms. Weakness or fatigue was the most pervasive symptom and almost  
223 one-third of participants reported fatigue after 22-28 days of illness. Between 10-20 percent of  
224 participants continued to have some degree of cough, headache, or anosmia as long as a month or more  
225 after the onset of symptoms. The prolonged duration of loss of taste and smell has been previously  
226 noted in the study using telephone surveys and is consistent with our prospective findings(6).

227  
228 While hospitalization was uncommon in our outpatient cohort, low ambulatory or resting oxygen  
229 saturation (<93%) were predictive for requiring subsequent hospitalization, suggesting a role for home  
230 pulse oximetry in outpatient management of COVID-19. We found that the initial SaO<sub>2</sub> value, a SaO<sub>2</sub>  
231 nadir during the first week of illness, or any SaO<sub>2</sub>, adjusting for duration of symptoms, is predictive of  
232 subsequent hospitalization. We found no major difference in the diagnostic yield between resting and  
233 ambulatory SaO<sub>2</sub> in this setting. The predictive value of outpatient oxygen saturation values have been  
234 previously described (5, 22). One study provided pulse oximeters to participants with COVID-19 who  
235 presented to an ED or outpatient testing centers; 29% required subsequent hospitalization. Low oxygen  
236 saturation detected on pulse oximetry was associated with hospitalization and more severe  
237 outcomes(22).

238

239 Although in the present study pulse oximetry was predictive of hospitalization, the measure alone often  
240 was not sufficient. Some persons needed hospitalization for non-respiratory symptoms (e.g. diarrhea)  
241 that logically were not detected by lower oxygen saturation. In addition, no single oxygen saturation  
242 reading alone predicted outcome as there was overlap in both the resting and ambulatory oxygen  
243 saturations of those who remained at home and those who were hospitalized. Therefore, pulse oximetry  
244 may be most useful as an adjunct to clinical monitoring of high risk populations such as those over 60  
245 years of age, males, and persons with elevated body mass index (5, 23).

246  
247 While this is the largest prospective outpatient cohort to characterize the clinical course of COVID-19,  
248 the study has several limitations. First, this study predominantly included older individuals to increase  
249 the statistical power for severe outcomes given the known association between age and  
250 hospitalization(12). Symptoms including severity and duration of illness may differ considerably in  
251 younger individuals and our results are more generalizable for persons of similar ages (24). Outpatients  
252 have been previously found to be younger and have less comorbidities compared to hospitalized  
253 patients(25). Second, the recruitment strategy may have skewed the study population. For instance,  
254 participants with milder symptoms and those with altruistic professions (e.g. healthcare workers) could  
255 have been more likely to participate in the study processes than others. A quarter of participants had  
256 symptoms of onset 10 days prior to enrollment, and therefore a proportion of participants may have  
257 been selected who had successfully passed a time window of disease severity. Additionally, due to  
258 operational requirements, Spanish-speakers were not enrolled proportionate to cases early after study  
259 initiation and individuals without active mobile phone access were not enrolled. Third, missing data  
260 from loss to follow-up or withdrawals during the study period could have skewed the longitudinal  
261 severity of results. For example, participants with milder illness could have been more likely to

262 withdrawal the course of the study. Despite limitations, our results help elucidate the progression of  
263 outpatient COVID-19.

264  
265 The prospective cohort provides additional insight into the clinical progression of outpatient COVID-19  
266 patients, who comprise the majority of patients with SARS-CoV-2 infection. Presenting symptoms were  
267 generally diverse and often persisted longer than expected for a respiratory virus. Hospitalization  
268 occurred among 7.6% and was associated with low home SaO<sub>2</sub> values, supporting the utility of pulse  
269 oximetry as a supplemental tool for remote clinical decision making. Given the diversity of  
270 manifestations of COVID-19, immunologic studies and longer-term follow-up of these patients is  
271 warranted to determine the extent of symptoms among those with persistent symptoms. There remains  
272 great uncertainty about the long-term effects of SARS-CoV-2 infection regardless of symptom severity.

273

#### 274 ACKNOWLEDGEMENT

275 We thank Dr. John Powers, Leidos Biomedical, the National Institute for Allergy and Infectious Diseases  
276 (NIAID), and the National Institutes of Health for supplying the FLU-PRO Questionnaire.

277

#### 278 REFERENCES

- 279 1. 2020 Pages <https://coronavirus.jhu.edu/data/new-cases> on 7 June, 2020.
- 280 2. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3,062 COVID-19  
281 patients: a meta-analysis. J Med Virol. 2020.
- 282 3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of  
283 Coronavirus Disease 2019 in China. N Engl J Med. 2020.
- 284 4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected  
285 with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.

- 286 5. Sun H, Jain A, Leone MJ, Alabsi HS, Brenner LN, Ye E, et al. COVID-19 Outpatient  
287 Screening: a Prediction Score for Adverse Events. medRxiv. 2020.
- 288 6. Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, et al. Symptom  
289 Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with  
290 COVID-19 in a Multistate Health Care Systems Network - United States, March-June  
291 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993-8.
- 292 7. Alwan NA. A negative COVID-19 test does not mean recovery. Nature. 2020;584:170.
- 293 8. Jouffroy R, Jost D, Prunet B. Prehospital pulse oximetry: a red flag for early detection of  
294 silent hypoxemia in COVID-19 patients. Crit Care. 2020;24(1):313.
- 295 9. Tobin MJ, Laghi F, Jubran A. Why COVID-19 Silent Hypoxemia is Baffling to Physicians.  
296 Am J Respir Crit Care Med. 2020.
- 297 10. Wilkerson RG, Adler JD, Shah NG, Brown R. Silent hypoxia: A harbinger of clinical  
298 deterioration in patients with COVID-19. Am J Emerg Med. 2020.
- 299 11. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of  
300 Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.  
301 JAMA Intern Med. 2020.
- 302 12. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United  
303 States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-6.
- 304 13. Vyse AJ, Cohen BJ, Ramsay ME. A comparison of oral fluid collection devices for use in  
305 the surveillance of virus diseases in children. Public Health. 2001;115(3):201-7.

- 306 14. Powers JH, Guerrero ML, Leidy NK, Fairchok MP, Rosenberg A, Hernández A, et al.  
307 Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate  
308 symptoms of influenza. *BMC Infect Dis.* 2016;16:1.
- 309 15. Yu J, Powers JH, 3rd, Vallo D, Falloon J. Evaluation of Efficacy Endpoints for a Phase IIb  
310 Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported  
311 Outcomes With Laboratory Confirmation. *Value Health.* 2020;23(2):227-35.
- 312 16. Powers JH, 3rd, Bacci ED, Guerrero ML, Leidy NK, Stringer S, Kim K, et al. Reliability,  
313 Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©)  
314 Scores in Influenza-Positive Patients. *Value Health.* 2018;21(2):210-8.
- 315 17. Han A, Poon JL, Powers JH, 3rd, Leidy NK, Yu R, Memoli MJ. Using the Influenza Patient-  
316 reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a  
317 healthy human challenge model. *BMC Infect Dis.* 2018;18(1):353.
- 318 18. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap  
319 consortium: Building an international community of software platform partners. *J*  
320 *Biomed Inform.* 2019;95:103208.
- 321 19. 2020;Pages[https://www.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-](https://www.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/)  
322 [19/case-definition/2020/](https://www.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/) on 29 July, 2020.
- 323 20. Carfi A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19.  
324 *Jama.* 2020;324(6):603-5.
- 325 21. Rimmer A. Covid-19: Impact of long term symptoms will be profound, warns BMA. *BMJ.*  
326 2020;370:m3218.

- 327 22. Shah S, Majmudar K, Stein A, Gupta N, Suppes S, Karamanis M, et al. Novel use of home  
328 pulse oximetry monitoring in COVID-19 patients discharged from the emergency  
329 department identifies need for hospitalization. *Academic Emergency Medicine*;n/a(n/a).
- 330 23. Hamer M, Gale CR, Kivimäki M, Batty GD. Overweight, obesity, and risk of  
331 hospitalization for COVID-19: A community-based cohort study of adults in the United  
332 Kingdom. *Proc Natl Acad Sci U S A*. 2020.
- 333 24. Scheuller HS, Park J, Lott L, Tavish M, Danaher P. Comparison of Clinical Features in a  
334 Population of Basic Military Trainees Versus the General Department of Defense  
335 Beneficiary Population Presenting With Influenza. *Mil Med*. 2017;182(9):e1917-e21.
- 336 25. Tenforde MW, Billig Rose E, Lindsell CJ, Shapiro NI, Files DC, Gibbs KW, et al.  
337 Characteristics of Adult Outpatients and Inpatients with COVID-19 - 11 Academic  
338 Medical Centers, United States, March-May 2020. *MMWR Morb Mortal Wkly Rep*.  
339 2020;69(26):841-6.
- 340

**Table 1.** Baseline demographics and clinical characteristics of cohort stratified by subsequent hospitalization.


Characteristic		Total	Subsequently Hospitalized	Ambulatory care
Male sex — no./total no. (%)		50/118 (42.4)	4/ 9 (44.4)	46/109 (42.2)
Age, Median (IQR) — yr		56.0 (50.0-63.0)	65.0 (54.0-69.0)	56.0 (49.0-62.0)
Race, no. (%)				
	White	56 (47.5)	7 (77.8)	49 (45.0)
	Black	46 (39.0)	1 (11.1)	45 (41.3)
	Other	8 (6.8)	0 (0.0)	8 (7.3)
	Asian	6 (5.1)	1 (11.1)	5 (4.6)
	Native American	1 (0.8)	0 (0.0)	1 (0.9)
	Native Hawaiian or other Pacific Islander	1 (0.8)	0 (0.0)	1 (0.9)
Ethnicity — no. (%)				
	Hispanic	18 (15.3)	3 (33.3)	15 (13.8)
Charlson Comorbidity Index, Median (IQR)		2 (1, 3)	2 (1, 3)	2 (1, 3)
Coexisting disorder — no. (%)				
	Hypertension	46 (39.0)	6 (66.7)	40 (36.7)
	Current or history of tobacco use	27 (26.0)	3 (33.3)	24 (25.3)
	Diabetes	19 (16.1)	3 (33.3)	16 (14.7)
	Asthma or COPD	18 (15.3)	2 (22.2)	16 (14.7)
	Solid tumor malignancy	18 (15.3)	1 (11.1)	17 (15.6)
	HIV	7 (6.6)	0 (0.0)	7 (7.2)
	Hematologic malignancy	6 (5.1)	0 (0.0)	6 (5.5)
	CKD stage 3 or 4	4 (3.4)	0 (0.0)	4 (3.7)
	History of myocardial infarction	2 (1.7)	1 (11.1)	1 (0.9)
Employment, no. (%)				
Healthcare setting				
	Hospital	15 (12.7)	0 (0.0)	15 (13.8)
	Skilled Nursing Facilities, Long-term Care Facility, or Nursing Home	9 (7.6)	0 (0.0)	9 (8.3)
	Clinic	3 (2.5)	0 (0.0)	3 (2.8)
	Other	3 (2.5)	0 (0.0)	3 (2.8)
	Home Health	2 (1.7)	0 (0.0)	2 (1.8)
	Prison or Jail	1 (0.8)	1 (11.1)	0 (0.0)
Essential worker, no. (%)		21 (20.6)	1 (14.3)	20 (21.1)
Body mass index, Median (IQR)		30.0 (26.0-36.0)	31.0 (29.0-36.0)	30.0 (25.0-36.0)
Duration of symptoms at enrollment, median (IQR) — days		5.0 (3.0-10.0)	3.0 (2.0-7.0)	6.0 (3.0-11.0)




---

Vital sign parameters			
Resting oxygen saturation (IQR) — %	98.0 (96.0-98.5)	95.0 (90.0-97.0)	98.0 (96.0-99.0)
Ambulatory oxygen saturation (IQR) — %	97.0 (95.0-98.0)	95.0 (88.0-96.0)	97.0 (96.0-98.0)
Heart rate (IQR) — beats per minutes	85.0 (74.0-91.0)	85.0 (73.0-94.0)	85.0 (74.0-91.0)
Highest temperature (IQR) — °Fahrenheit	98.3 (97.6-98.8)	98.4 (97.9-100.2)	98.3 (97.6-98.8)

---




**Figure 1.** Screening, enrollments, and follow-up.




**Figure 2.** (A) Symptom prevalence by week of illness per a FLU-PRO questionnaire and additional COVID-19 specific questions and (B) violin plots of symptom duration centered by onset of the first symptom(s) to illustrate the course of disease over time from questionnaire responses during the study period

\*Not present in interim April 2020 CDC COVID-19 case definition.



**Figure 3.** Kaplan-Meier curve of time to participants returning to usual activities (A) and to usual health (B).

Severity of disease during first month of illness among those with symptomatic outpatient COVID-19 including (C) perception of disease, (D) perception of health, and (E) the effect on usual activities.



**Figure 4.** Box plots of resting (A) and ambulatory (B) oxygen saturation (%) at enrollment among those that subsequently were hospitalized and those that were not during the study period. Outpatient vital signs over time by duration of symptoms stratified by subsequent hospitalization requirement including (C) resting oxygen saturation, (D) ambulatory oxygen saturation, (E) heart rate (beats per minute), and (F) temperature (degrees Fahrenheit).